Clinipace Worldwide Expands European Operations with Acquisition of Accovion
Accovion Strengthens Clinipace’s Operational and Therapeutic Expertise Within Europe
MORRISVILLE, N.C. (Business Wire) April 13, 2015 – Clinipace Worldwide, a global digital contract research organization (dCRO), announced today the completion of its merger with Accovion, a leading European full-service CRO headquartered in Frankfurt (Eschborn), Germany.
Accovion provides the entire range of clinical research services to the pharmaceutical, biotechnology and medical device industries. For more than 10 years, Accovion has been successfully conducting clinical trials across all phases of clinical development and is currently active in more than 20 countries. Bringing these organizations together strengthens Clinipace Worldwide’s operational and therapeutic expertise in Europe, with strong back-end and front-end services, and expands the company’s footprint to additional countries including Russia, Italy, Czech Republic, Romania, Poland, Spain, France and Ukraine.
Dr. Andree Beckerling, the CEO of Accovion, will have day-to-day operating responsibility for all of the European offices, including existing Clinipace staff and locations. Beckerling will report to Clinipace CEO, Jeff Williams, and will join the company’s Executive Committee (EC).
“Life science firms, and the CRO industry that serves them, continue to undergo significant change. To be competitive in today’s market, it is important to have, among other things, a strong multi-national scale, broad therapeutic expertise and a better service delivery model,” observed Williams, CEO, Clinipace Worldwide. “Bringing our companies together substantially enhances our existing European footprint throughout western, central and eastern Europe and enables us to offer a competitive array of global clinical development and regulatory services in these regions. Supported by our technology-amplified dCRO delivery model, we now have a very compelling value proposition for sponsors looking for support in these markets.”
“Finding a partner that shared the same common business philosophy, values and quality expectations that provided our clients access to the United States and global markets was essential to our long-term success,” remarked Beckerling, CEO, Accovion. “Clinipace provides the right combination of complementary operational strengths, services and geography. Accovion clients gain access to Clinipace’s dCRO delivery model supported by their proprietary TEMPO™ eClinical platform and a comprehensive and integrated clinical operations, data management, biostatistics and regulatory consultancy with a large worldwide footprint.”
Today’s announcement marks the sixth acquisition by Clinipace in recent years. Together, Clinipace Worldwide will now be home to nearly 1,000 global staff. The combined company has managed over 3,000 clinical research studies and more than 300 regulatory and strategic development engagements.
Combined with Accovion, Clinipace now has clinical operations and staff in 39 countries. European operations are based in Frankfurt, Munich and Marburg, Germany; Prague, Czech Republic; Krakow, Poland; Timisoara, Romania; Moscow, Russia; Zurich, Switzerland; Milan, Italy; Lyon, France; Madrid, Spain; London, United Kingdom; and Kiev, Ukraine.
Terms of the transaction will not be disclosed.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
